🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating globally, with data suggesting more than 82 million instances per year. Especially elevated rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices at this time.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Data and Worldwide Availability

Based on results published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in numerous developing nations.

Medical professionals on the front lines have voiced positive views. Access to a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.